Menu Search
Equities

AnaptysBio Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0HFQ:LSE

AnaptysBio Inc

Actions
  • Price (USD)47.28
  • Today's Change-3.68 / -7.22%
  • Shares traded84.00
  • 1 Year change+285.02%
  • Beta0.3460
Data delayed at least 20 minutes, as of Feb 11 2026 15:17 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

  • Revenue in USD (TTM)169.47m
  • Net income in USD-84.63m
  • Incorporated2005
  • Employees136.00
  • Location
    AnaptysBio Inc10770 WATERIDGE CIRCLE, SUITE 210SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 362-6295
  • Fax+1 (858) 362-6296
  • Websitehttps://www.anaptysbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.